ArticleClinical research in cardiology : official journal of the German Cardiac Society2015
Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 80 citations in OpenAlex.
- Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED.Journal of the American Heart Association · 2026Trial
- Prioritised endpoints for device-based hypertension trials: the win ratio methodology.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2021Trial
- Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial.British journal of clinical pharmacology · 2018Trial
- Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency.Cardiovascular revascularization medicine : including molecular interventionsTrial
- Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Not obtaining a medication the first time it is prescribed: primary non-adherence to cardiovascular pharmacotherapy.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Review
- The Simplified Medication Adherence Questionnaire: validation of a Brazilian-Portuguese version in hypertensive adults.Frontiers in pharmacology · 2024Article
- Chemical adherence testing in the clinical management of hypertension: a scoping review.Frontiers in pharmacology · 2024Article
- Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis.Molecules (Basel, Switzerland) · 2021Article
- Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies.European heart journal · 2020Article
- Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and β-blockers - drug classes with low adherence in antihypertensive therapy.Scientific reports · 2019Article
- Renal Denervation: Is It Ready for Prime Time?Current cardiology reports · 2019Review
- Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening.Patient preference and adherence · 2019Review
- Medication adherence and treatment-resistant hypertension: a review.Drugs in context · 2019Review
- Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk.Patient preference and adherence · 2019Article
- Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model.Journal of hypertension · 2018Article
- Hypertension: history and development of established and novel treatments.Clinical research in cardiology : official journal of the German Cardiac Society · 2018Review
- Impact of renal denervation on tissue NaClinical research in cardiology : official journal of the German Cardiac Society · 2018Observational
- Primary nonadherence to chronic disease medications: a meta-analysis.Patient preference and adherence · 2018Review
- Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.European heart journal · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal denervation can reduce blood pressure in patients with uncontrolled hypertension. The adherence to prescribed antihypertensive medication following renal denervation is unknown. This study investigated adherence to prescribed antihypertensive treatment by liquid chromatography-high resolution tandem mass spectrometry in plasma and urine at baseline and 6 months after renal denervation in 100 patients with resistant hypertension, defined as baseline office systolic blood pressure ≥140 mmHg despite treatment with ≥3 antihypertensive agents. At baseline, complete adherence to all prescribed antihypertensive agents was observed in 52 patients, 46 patients were partially adherent, and two patients were completely non-adherent. Baseline office blood pressure was 167/88 ± 19/16 mmHg with a corresponding 24-h blood pressure of 154/86 ± 15/13 mmHg. Renal denervation significantly reduced office and ambulatory blood pressure at 6-month follow-up by 15/5 mmHg (p < 0.001/p < 0.001) and 8/4 mmHg (p < 0.001/p = 0.001), respectively. Mean adherence to prescribed treatment was significantly reduced from 85.0 % at baseline to 80.7 %, 6 months after renal denervation (p = 0.005). The blood pressure decrease was not explained by improvements in adherence following the procedure. Patients not responding to treatment significantly reduced their drug intake following the procedure. Adherence was highest for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta blockers (>90 %) and lowest for vasodilators (21 %). In conclusion, renal denervation can reduce office and ambulatory blood pressure in patients with resistant hypertension despite a significant reduction in adherence to antihypertensive treatment after 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.